At the recent AACR Conference on Pancreatic Cancer, Kevan M. Shokat, PhD, FAACR, received the 2026 Stephenson Global Prize...
“Do you want to have fun?” Richard Pazdur, MD, director of the U.S. Food and Drug Administration (FDA) Oncology...
Immune checkpoint inhibitors have become part of the standard of care for more than 14 different cancer types, including...
During the third quarter of 2026, the U.S. Food and Drug Administration approved cancer treatments that expanded the options...
Featuring insights from Carl H. June, MD, FAACR, this post covers the ongoing challenges facing CAR T-cell therapy and...
The August 2026 Editors’ Picks from AACR journals cover the impact of weight loss and omega-3 supplementation on breast...
Ovarian cancer is often diagnosed at an advanced stage, but research is reshaping how scientists understand and treat the...
In July, the editors from AACR's 10 peer-reviewed journals highlighted research on AI-driven molecular mapping of pancreatic cancer evolution,...
During the second quarter of 2026, oncology approvals issued by the U.S. Food and Drug Administration expanded the treatment...
The June edition of Editors’ Picks from the AACR journals included studies on targeting neural cross-talk to stop glioblastoma...
In May, AACR's journals editors highlighted studies on CD28’s impact on CAR T-cell activity, the relationship between neurons and...